Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. - Burger, Jan A.; Robak, Tadeusz; Demirkan, Fatih; Bairey, Osnat; Moreno, Carol; Simpson, David; Munir, Talha; Stevens, Don A.; Dai, Sandra; Cheung, Leo W. K.; Kwei, Kevin; Lal, Indu; et al. (Leukemia & Lymphoma, 2022)